经直肠超声引导13点法前列腺穿刺活检术诊断前列腺癌

目的：评价经直肠超声引导13点法前列腺系统穿刺活检术诊断前列腺癌的临床价值。方法：按照Eskew描述的方法,在标准的经直肠超声引导6点法前列腺系统穿刺活检术的基础上,增加在前列腺的中间部位及前列腺两侧旁正中线远侧的穿刺点数,总共穿刺活检13处。将增加的7处活检部位的病理结果与标准的6点法前列腺系统穿刺活检术进行比较,并对经直肠超声引导13点法前列腺系统穿刺活检术的并发症进行了讨论。结果：总共51例患者中有20例确诊为前列腺癌（20/51）,占39%,此20例前列腺癌患者若仅采用标准的经直肠超声引导6点法前列腺系统穿刺活检术,将有5例患者漏诊,占25%。所有接受经直肠超声引导13点法法前列腺系统穿刺活检术的患者无一例出现严重的并发症。结论：经直肠超声引导13点法前列腺系统穿刺活检术可明显提高前列腺癌的临床检出率,是一种安全、有效的前列腺系统穿刺活检术式,值得在临床推广应用。     

B超引导下经直肠前列腺穿刺活检低回声区穿刺要点

目的 探讨临床上B超引导下经直肠前列腺穿刺活检低回声区穿刺要点.方法 回顾性分析本院343例B超提示前列腺低回声患者行经直肠前列腺穿刺活检术的临床资料.结果 前列腺癌210例,阳性率为61.22％.结论 对B超提示前列腺低回声患者行经直肠前列腺低回声区穿刺活检术,可提高检出率.     

超声引导下经直肠10针前列腺穿刺活检对前列腺癌诊断的研究

目的 探讨超声引导下经直肠10针前列腺穿刺活检术诊断前列腺癌的临床应用价值。方法 回顾性分析104例经直肠10针穿刺活检的可疑前列腺癌患者。在标准6针系统穿刺法基础上改进确定A组穿刺点后,依据前列腺解剖分区,在经直肠B超显示的前列腺冠状切面的两侧外侧区域（B组）及中央区域（C组）增加4针穿刺点,施行前列腺活检,病例标本分别标注送病理学检查。结果 104例患者中42例确诊为前列腺癌,总阳性率为40.4%。其中所设置的A组穿刺位点阳性25例（占总检出阳性的59.5%）,B组位点阳性9例（21.4%）,C组位点阳性8例（19.0%）。假阴性率为4.7%,术后并发症总发生率为15.4%,未出现严重并发症。结论 超声引导下经直肠10针前列腺穿刺活检术安全、可靠,可以作为临床理想的初次前列腺穿刺活检术式之一。     

B超引导穿刺活检诊断前列腺癌

Ｂ超引导穿刺活检诊断前列腺癌朱刚王建业万奔魏庆国应用经直肠Ｂ超（ＴＲＵＳ）引导前列腺穿刺活检技术，结合直肠指诊（ＤＲＥ）、前列腺特异抗原（ＰＳＡ）和经直肠Ｂ超检查，对３８例怀疑前列腺癌的病人进行诊断，报告如下。资料与方法自１９９６年４月～１９９７年４...     

经直肠超声引导下“10+X”点法前列腺穿刺活检术在PSA值介于4～20ng/ml之间患者前列腺癌诊断中的价值

目的 探讨经直肠超声引导下“10 +X”前列腺穿刺活检术在PSA值介于4 ～20ng/ml之间患者前列腺癌诊断中的价值。方法 回顾性分析226例血清PSA值介于4～20ng/ml之间疑似前列腺癌患者临床资料,所有患者均行经直肠超声引导下前列腺穿刺术活检。结果 前列腺癌47例,前列腺增生158例,前列腺炎11例,前列腺上...     

6针法和13针法前列腺穿刺活检术诊断前列腺癌的分析比较

目的探讨5区13针法和6针法前列腺穿刺活检诊断前列腺癌的差异。方法本组214例,因前列腺特异性抗原>4.0ng/ml或直肠指诊前列腺癌阳性可疑而行13针前列腺穿刺活检术,其中前列腺特异性抗原>4.0ng/ml者203例,直肠指诊前列腺癌阳性可疑者41例。入选病例的年龄为50￣90岁,平均69.8岁;PSA水平0.8￣112.3ng/ml,平均18.7ng/ml;前列腺体积12.3￣182.5ml,平均61.3ml;直肠指诊阴性者173例,阳性者41例。结果6针法和13针法的阳性率分别为30.8(f/214)和36.0(w/214),后者的阳性率提高14.3(/77()P<0.001)。两者的差异在前列腺特异性抗原≤20ng/ml,指诊阴性,体积>40ml,前列腺特异性抗原密度≤0.30,年龄<70岁的患者中更显著。结论5区13针前列腺穿刺活检术比系统6针发现前列腺癌的阳性率更高。     

经直肠超声引导前列腺穿刺活检的并发症

前列腺癌的早期诊断是降低其病死率的关键。一般认为经直肠超声引导前列腺穿刺活检（ＴＲＵＰＢ）是诊断前列腺癌的常规安全检查方法,但随着此方法的临床广泛应用发现也有不少并发症,发生率可高达 ６４％～７８％［１］。常见的并发症有感染、出血、疼痛和血管迷走神经症状。１感染 ＴＲＵＰＢ最严重的并发症是菌血症,发生率为１６％～７３％,而菌尿的发生率为２０％～５３％,预防应用抗生素可降低感染的发生率［２］。Ｔｈｏｍｐｓｏｎ等［３］对ＴＲＵＰＢ所用穿刺针针尖及患者血液培养发现,引起感染最常见的细菌为厌氧菌中的杆菌类…     

超声引导下经会阴与经直肠前列腺穿刺活检在前列腺癌诊断中的应用价值

目的 对比分析B超引导下经会阴前列腺穿刺活检(TPBx)与经直肠前列腺穿刺活检(TRBx)在前列腺癌诊断中的应用效果,从而为临床选择合适前列腺穿刺方法提供依据.方法 选择本院2012年11月至2015年12月临床疑似前列腺癌患者171例作为研究对象,根据患者的穿刺方式分为经会阴组(TPBx) 89例和经直肠组(TRBx) 82例,分析肿瘤检出率、并发症发生率、疼痛评分、手术时间.结果 TPBx组和TRBx组在肿瘤检出率、总体并发症发生率方面没有差异,直肠出血TRBX组发生率更高,而TPBx组疼痛发生率高,手术时间长于TRBX组.结论 TPBx和TRBx都能有效地检出前列腺癌,TRBx发生直肠出血较多,而TPBx需要更长的操作时间和增加疼痛.     

前列腺穿刺活检的适应证

前列腺穿刺活检是诊断前列腺癌的金标准,但穿刺活检的适应证仍有争议。本文就前列腺穿刺活检适应证的最新进展作一综述。包括直肠指检,前列腺特异性抗原水平及其相关指标以及首次活检为前列腺上皮内瘤或不典型增生等。并初步介绍肿瘤标记物PCA3基因以及人工神经网络在诊断早期前列腺癌中的作用。     

前列腺穿刺活检的适应证

前列腺穿刺活检是诊断前列腺癌的金标准,但穿刺活检的适应证仍有争议。本文就前列腺穿刺活检适应证的最新进展作一综述。包括直肠指检,前列腺特异性抗原水平及其相关指标以及首次活检为前列腺上皮内瘤或不典型增生等。并初步介绍肿瘤标记物PCA3基因以及人工神经网络在诊断早期前列腺癌中的作用。     

Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol

OBJECTIVE: To compare, in a prospective study, bleeding (in three categories, i.e. haematuria, haematospermia and rectal) and consultations with the general practitioner (GP), after a six-, eight- or 12-core prostate biopsy, as data on whether taking more prostate core biopsies increases bleeding complications are not conclusive. PATIENTS AND METHODS: Over a 5-year period, patients undergoing outpatient transrectal ultrasonography (TRUS)-guided prostate biopsy (six, eight or 12-core biopsy) completed a self-administered questionnaire. The prevalence and duration of the three bleeding complications and GP or hospital visits for a biopsy-related complication were assessed and compared for the 7 days after biopsy. The contribution of local anaesthetic (LA) injection to bleeding rates was also assessed. RESULTS: Of 1384 patients biopsied, 1000 were given questionnaires and 884 (88%) forms were returned. Of these, 760 were suitable for analysis (307 after six-core, 325 eight-core and 128 12-core biopsies); 351 patients were given LA before biopsy. The prevalence of bleeding complications (six-, eight- and 12-core, respectively) was: haematuria 44%, 41% and 39%; haematospermia 13%, 16% and 12%; and rectal bleeding 17%, 26% and 27%. Rectal bleeding was significantly more prevalent in the eight- and 12-core groups (P = 0.0037 and 0.019). The duration of bleeding was not significantly greater in any biopsy group. Subgroup analysis showed no significant difference in the prevalence and duration of rectal bleeding after LA. About 5% of patients in each group consulted their GP because of a complication and 2.4% consulted because of bleeding. Three men with major complications required hospitalization, of which only one was caused by bleeding. CONCLUSIONS: Only rectal bleeding was more prevalent after taking more than six cores, but the duration was no greater. Giving LA did not affect the rectal bleeding rate. With all strategies the major complication and hospitalization rate was very low.     

Extensive biopsy using a combined transperineal and transrectal approach to improve prostate cancer detection

PURPOSE: Previous studies have indicated that 6-core transrectal prostate biopsy misses a considerable number of cancers. We performed an extensive biopsy protocol of 12-core sampling using both transperineal and transrectal approaches to determine the impact on the cancer detection rate. MATERIALS AND METHODS: We prospectively evaluated 402 men who underwent 6-core transperineal and 6-core transrectal biopsies simultaneously due to abnormal digital rectal examination (DRE) and/or elevated prostate-specific antigen (PSA) levels of 4.0 ng/mL or greater. Using the transperineal approach we obtained four cores from the bilateral peripheral zone targeting the lateral and parasagittal areas and two cores from the bilateral transition zone. The following transrectal biopsy was performed traditionally. We compared cancer detection rate between the extended 12-core procedure and conventional 6-core transperineal and transrectal groups in terms of total PSA and DRE findings. RESULTS: Using the extensive combined method, prostate cancer was detected in 195 cases (48.5%) and the detection rate significantly increased 7.2% and 8.5% compared to the transperineal and transrectal groups, respectively. According to PSA levels and DRE findings, the cancer detection rate by the combined method was significantly improved in patients with PSA levels of 4-10 ng/mL and negative DRE: 10.3% and 11.6% compared to the transperineal and transrectal groups, respectively. CONCLUSIONS: The extensive 12-core method significantly improved the overall cancer detection rate and was especially efficient for men with PSA levels of 4-10 ng/mL accompanied by a negative DRE finding.     

穿刺标本Gleason评分预测前列腺癌病理分级准确性的研究

目的 分析前列腺癌患者穿刺标本与根治术标本Gleason评分的相关性,探讨影响穿刺标本Gleason评分准确性的可能因素.方法 回顾性分析86例接受根治性前列腺切除术的前列腺癌患者资料,比较穿刺标本与根治术标本Gleason评分的符合情况,应用二分类Logistic回归分析筛选影响穿刺标本Gleason评分准确性的可能因素.结果 86例患者穿刺标本平均Gleason评分为6.1,根治术标本平均Gleason评分为6.5,穿刺标本与根治术标本Gleason评分相比,评分相符42例(48.8%),评分偏低32例(37.2%),评分偏高1 2例(14.0%),差异具有统计学意义(P＜0.05),偏差与患者年龄、血清PSA、前列腺体积、临床分期无显著相关性(P＞0.05),与穿刺针数(OR=2.905)及穿刺阳性率(OR=4.225)有显著相关(P＜0.05).结论 穿刺针数与穿刺阳性针数百分比是影响穿刺标本Gleason评分准确性的可能因素,增加前列腺穿刺活检针数将可能有助于提高穿刺标本预测前列腺癌病理分级的准确性.     

经直肠与经会阴途径穿刺活检诊断前列腺癌的对比分析

目的比较经直肠途径与经会阴途径穿刺活检对前列腺癌(PCa)的检出率。方法回顾性收集128例首次确诊的PCa患者,根据活检途径不同,分为经直肠途径组62例和经会阴途径组66例,比较2种途径诊断不同总前列腺特异性抗原(TPSA)水平PCa及临床意义前列腺癌(CsPCa)检出率的差异。对其中104例(经直肠途径组42例,经会阴途径组62例)在常规超声检查基础上行CEUS,于83例(经直肠途径组28例,经会阴途径组55例)检出阳性病灶后行靶向穿刺,比较2组系统穿刺及靶向穿刺PCa、CsPCa的检出率。结果经直肠途径组PCa检出率为35.48%(22/62),CsPCa检出率为25.81%(16/62);经会阴途径组PCa检出率为42.42%(28/66),CsPCa检出率为28.79%(19/66),差异均无统计学意义(P=0.471、0.676);2组对不同TPSA水平PCa及CsPCa的检出率差异均无统计学意义(P均0.05)。经直肠途径组与经会阴途径组在系统穿刺中PCa检出率[35.48%(22/62) vs 40.91%(27/66);P=0.587]、阳性针数/总针数[14.25%(106/744) vs 14.52%(115/792);P=0.879]、CsPCa检出率[25.81%(16/62) vs 28.79%(19/66);P=0.676]差异均无统计学意义;靶向穿刺活检PCa检出率[35.71%(10/28) vs 14.55%(8/55);P=0.002]、阳性针数/总针数[30.77%(24/78) vs 6.76%(10/148);P0.001]差异有统计学意义。结论超声引导下前列腺穿刺活检经直肠途径与经会阴途径对PCa及CsPCa检出率无差异。CEUS可引导前列腺靶向穿刺活检,穿刺操作时选择与CEUS相同的患者体位及解剖断面可提高PCa检出率。     

经直肠超声引导前列腺穿刺活检术诊断前列腺癌

目的　总结和评价经直肠超声引导下前列腺穿刺活检术对前列腺癌诊断的准确率。方法　222 例直肠指检阳性或 PSA>4μg/L的患者应用经直肠超声引导下前列腺6点系统穿刺活检以明确诊断。结果　222 例受检者中病理证实前列腺结节性增生41例、前列腺炎24例、前列腺肉瘤3例、前列腺癌 154 例,其中低分化癌 74 例、中分化癌 58 例、高分化癌 22 例。术后血尿15例、发热6例,其中高热1例,经抗生素治疗后体温恢复正常、尿检阴性。结论　经直肠超声引导下前列腺穿刺活检无需麻醉,患者痛苦小、安全性高,是诊断前列腺癌的可靠方法。     

Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer

Study Type – Diagnostic (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? The widespread use of serum PSA testing followed by TRUS‐guided biopsy have resulted in profound prostate cancer stage migration with many patients presenting with focal rather than multifocal disease. There is increasing interest in the use of focal rather than whole‐gland treatment. However, current biopsy schemes may still miss cancer or, even when cancer is identified, its extent or grade might not be accurately characterized. In order for focal therapy to be effective, the area of highest tumour volume and/or grade needs to localized accurately. The aim of this study was to assess how well biopsy, as currently performed, locates the focus of highest prostate cancer volume and/or grade.

OBJECTIVE

• ? To evaluate the ability of transrectal ultrasonography (TRUS)‐guided extended core biopsy to identify the dominant tumour accurately in men with early stage prostate cancer.

PATIENTS AND METHODS

• ? Patients with early stage, low‐risk prostate cancer who subsequently underwent radical prostatectomy (RP) and had complete surgical specimens were identified.
• ? Re‐review was performed by a single uropathologist using ImageJ software to identify tumour location, dominant grade (DG) and dominant volume (DV).
• ? Pathology findings were then compared with biopsy results.

RESULTS

• ? A total of 51 men with early stage, low‐risk prostate cancer, who had undergone RP, had complete specimens for review and a median of 15 biopsy cores taken for diagnosis and grading.
• ? Sixteen men had a single diagnostic biopsy, 21 had one repeat biopsy, and 14 had two or more repeat biopsies.
• ? Compared with surgical findings, biopsy correctly identified the sextant with the largest tumour volume in 55% (95% CI 0.5–0.6) of specimens and the highest grade in 37% (95 CI 0.3–0.5).
• ? No demographic or clinical factors were significantly associated with identification of DG. Interval between last biopsy and RP, total tissue length taken and total length of tumour identified were significantly associated with correct identification of DV.

CONCLUSIONS

• ? Our findings show that TRUS‐guided biopsy detects and localizes DV better than it does DG.
• ? Even with an extended scheme, TRUS‐guided biopsy does not reliably identify dominant cancer location in this low‐risk cohort of men with early stage prostate cancer.
• ? TRUS‐guided biopsy may perform better in similar men with low stage, but higher volume disease.

     

Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer

OBJECTIVE

To explore the ability of a novel transrectal ultrasonography (TRUS) device (TargetScan^TM, Envisioneering Medical Technologies, St. Louis MO) that creates a three‐dimensional map of the prostate and calculates an optimal biopsy scheme, to accurately sample the prostate and define the true extent of disease, as standard TRUS‐guided prostate biopsy relies on the operator to distribute the biopsy sites, often resulting in under‐ and oversampling regions of the gland.

PATIENTS AND METHODS

In a multicentre retrospective chart review evaluating patients who had a TargetScan prostate biopsy between January 2006 and June 2007, we determined the overall cancer detection rate in all patients and in subgroups based on prostate specific antigen level, digital rectal examination, and indication for biopsy. We assessed the pathological significance of cancer detected, defined as a Gleason score of ≥7, positive margins, extracapsular disease or >20% tumour volume in the prostatectomy specimen. We also evaluated the concordance in Gleason score between the biopsy and prostatectomy specimen.

RESULTS

Cancer was detected in 50 (35.7%) of the 140 patients biopsied, including 39 (47.6%) with no previous biopsies. Of 23 prostatectomy specimens, 20 (87%) had pathologically significant disease. The biopsy predicted the prostatectomy Gleason score in 12 patients (52%), overestimated in two (9%), underestimated in eight (35%), and biopsy Gleason score could not be assigned in one (4%).

CONCLUSIONS

Template‐guided biopsy potentially produces a higher cancer detection rate and more accurate assessment of grade. Prostatectomy specimens did not have a high rate of pathologically insignificant disease.     

Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review

PURPOSE: Several new extended prostate biopsy schemes (greater than 6 cores) have been proposed. We compared the cancer detection rates and complications of different extended prostate biopsy schemes for diagnostic evaluation in men scheduled for biopsy to identify the optimal scheme. MATERIALS AND METHODS: In a systematic review we searched 13 electronic databases, screened relevant urological journals and the reference lists of included studies, and contacted experts. We included studies that compared different systematic prostate biopsy methods using sequential sampling or a randomized design in men scheduled for biopsy due to suspected prostate cancer. We pooled data using a random effects model when appropriate. RESULTS: We analyzed 87 studies with a total of 20,698 patients. We pooled data from 68 studies comparing a total of 94 extended schemes with the standard sextant scheme. An increasing number of cores were significantly associated with the cancer yield. Laterally directed cores increased the yield significantly (p = 0.003), whereas centrally directed cores did not. Schemes with 12 cores that took additional laterally directed cores detected 31% more cancers (95% CI 25 to 37) than the sextant scheme. Schemes with 18 to 24 cores did not detect significantly more cancers. Adverse events for schemes up to 12 cores were similar to those for the sextant pattern. Adverse event reporting was poor for schemes with 18 to 24 cores. CONCLUSIONS: Prostate biopsy schemes consisting of 12 cores that add laterally directed cores to the standard sextant scheme strike the balance between the cancer detection rate and adverse events. Taking more than 12 cores added no significant benefit.